



Tamsin M. Lindstrom1,2,* and William H. Robinson1,2,*
1Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
*Correspondence: tlind@stanford.edu (T.M.L.), wrobins@stanford.edu (W.H.R.)
DOI 10.1016/j.cell.2010.12.022
Current efforts to identify antibodies that are biomarkers of disease rely on knowing the antigens
they target. In many diseases, however, the relevant antigens are unknown. Reddy et al. (2010)
now present an approach for discovering antibody biomarkers that avoids the need for antigen
identification.Biomarkers, objective indicators of a
specificbiological state, have thepotential
to illuminate the pathogenesis of disease
and to transform its management. Bio-
markers may aid in diagnosing disease,
predicting disease onset, and selecting
appropriate therapy. However, with a few
exceptions, this promise has yet to be ful-
filled (Rifai et al., 2006)—partly because,
for many diseases, molecular biomarkers
have yet to be identified. Antibodies are
one typeofmolecular biomarker. Because
antibodies function by binding specific
antigens, attempts to identify antibody
biomarkers have so far involved using
antigens to capture antibodies that are
overproduced in disease. The problem
with this approach is that in many dis-
eases, particularly autoimmune diseases,
the antigen that triggers the immune
response is unknown. In this issue of
Cell, Reddy et al. (2010) report a new
approach for the discovery of antibody
biomarkers, one that requires no knowl-
edge of the specificity of the immune
response. Instead of putative antigens,
the authors use an array of random
synthetic molecules to pinpoint disease-
associated antibodies (see Figure 1).
Identifying relevant antigens is at the
heart of current approaches for discov-
ering antibody biomarkers. Array-based
approaches depend on exposing serum
samples from patients to an ordered array
of putative antigens, capturing those anti-
bodies that bind antigens on the arrays,
and measuring their levels (Robinson
et al., 2002). Antibodies that are present
at significantly higher levels in the serum
of patients with the disease of interest(compared to control serum from either
healthy patients or patients with an unre-
lated disease) are candidate biomarkers.
One major drawback of these antigen
arrays is that they are biased, given
that antigens are selected based on the
likelihood that they play a role in the
disease. Antigen arrays are thus ill-suited
to de novo discovery. Less biased are
the high-density antigen arrays, which
comprise clones of a human cDNA library
expressed in bacterial or insect cells
(Auger et al., 2009; Horn et al., 2006).
However, because they comprise either
recombinant proteins or biomolecules
isolated from tissues irrelevant to the
disease, neither high-density nor conven-
tional antigen arrays recapitulate the
spectrum of posttranslational modifica-
tions that can occur in humans. This omis-
sion is another major drawback because
many of the antigens that play a role
in autoimmune disease are molecules
with posttranslational modifications that
elicit disease only in their modified form
(Doyle and Mamula, 2001). Unlike array-
based approaches, mass-spectrometric
approaches start with the extraction
of biomolecules directly from diseased
tissues and thus do take into account
relevant posttranslational modifications.
Immunoblotting with antibodies from
patients’ sera can then pinpoint specific
disease antigens, which can be identi-
fied using mass spectrometry (Wu and
Mohan, 2009). Nonetheless, mass-spec-
trometric approaches suffer from their
own set of drawbacks; for instance, the
selection of the diseased tissue to be
analyzed, as well as imperfections inCell 1antigen isolation and sample preparation,
introduce some bias.
Reddy et al. tackle the problem from
a new angle, devising an unbiased, high-
throughput approach that is predicated
on posttranslational modification. They
keep the array format and readout the
same as that of current antigen arrays
but change the content of the arrays—
the antibody bait. They reason that the
primary antigens (those that trigger the
initial immune response) are most likely
to be biomolecules that are not onlymodi-
fied but modified in an abnormal way,
owing to a pathological process charac-
teristic of the disease. This concept reso-
nates with current thinking, for instance
about rheumatoid arthritis, an autoim-
mune disease affecting the joints. A key
target of the aberrant antibody response
in rheumatoid arthritis is a protein that
has undergone citrullination (Whiting
et al., 2010), a posttranslational modifica-
tion that occurs during inflammation
and cell death. So rather than use unmod-
ified biomolecules, the authors use a
combinatorial library of unnatural, syn-
thetic molecules that might by chance
mimic the antibody-binding site of the
primary antigen. The premise is that these
synthetic molecules, termed peptoids,
can form shapes that cannot be formed
by unmodified biomolecules. Through
mimicry, then, peptoids might be able to
pinpoint antibodies that are important to
the disease process and thus aid in the
discovery of biomarkers.
To test their hypothesis, Reddy et al.
initially use arrays of 4608 different pep-
toids to fish for antibodies associated44, January 7, 2011 ª2011 Elsevier Inc. 13
Figure 1. Using Peptoids to Discover Antibody Biomarkers of Disease
Reddy et al. (2010) describe a new approach for identifying antibody biomarkers of disease. They use
arrays of syntheticmolecules termed peptoids to capture antibodies frompatients’ serum. Tomeasure the
levels of the IgG antibodies they capture, the authors use a fluorescently labeled anti-IgG antibody. A
peptoid (Peptoid X) that by chance mimics the antibody-binding site of a key disease antigen will retain
much more antibody from patients’ serum than from normal (nondiseased) serum. Antibody binding to
Peptoid X could then serve as a marker of disease. In separate experiments, it may be possible to identify
the endogenous target of the captured antibody by using the antibody to fish its antigen out of serum.with experimental autoimmune encepha-
lomyelitis (EAE), a mouse model of multi-
ple sclerosis (an autoimmune disease
targeting myelin sheaths). They identify
three peptoids (named AMogP1–3, after
the Mog peptide used to induce EAE
in mice) that bind much more antibody
in serum from mice with EAE than in
serum from healthy mice, control mice
immunized with ovalbumin, or mice with
systemic lupus erythematosus, another
autoimmune disease. The authors go
on to show that antibody binding to
AMogP1–3 can differentiate between
healthy mice and mice with EAE. These
results define antibody binding to
AMogP1–3 as a biomarker of EAE.
Although one particular antigen (the
primary antigen) triggers the initial anti-
body response in autoimmune disease,14 Cell 144, January 7, 2011 ª2011 Elsevier Iadditional antigens (secondary antigens)
form as the disease progresses, leading
to the production of additional anti-
bodies. Compared to antibodies against
secondary antigens, antibodies against
the primary antigen are more likely to be
specific to the disease and to therefore
serve as biomarkers. If the antibodies
that bind AMogP1–3 recognize the
primary antigen in EAE, then Mog should
be their endogenous target. The authors
garner two pieces of evidence showing
that this is the case. First, they show that
antibody reactivity to AMogP1–3 arises
at the same time as the reactivity to Mog
itself. Second, and more importantly,
serum from EAE mice (which have been
immunized with Mog) no longer reacts
with AMogP1–3 once it has been depleted
of anti-Mog antibodies. These findingsnc.provide proof of concept that an unnatural
molecule can uncover the antibody that
recognizes a disease-triggering antigen.
But can such a peptoid-based ap-
proach be applied to human disease,
which is much more varied than the
carefully controlled disease induced in
genetically identical laboratory mice? To
address this question, the authors turn
to Alzheimer’s disease. Although not
classically considered an autoimmune
disease, Alzheimer’s disease involves
aberrations in levels of antibodies against
b-amyloid (Britschgi et al., 2009) and ATP
synthase (Vacirca et al., 2010). By
screening serum samples against 15,000
peptoids, Reddy et al. identify three pep-
toids that can distinguish patients with
Alzheimer’s disease from age-matched
healthy individuals. If further studies vali-
date antibody binding to these peptoids
as a biomarker of Alzheimer’s (through
evaluation in independent patient cohorts
and in a larger number of samples),
this new assay could greatly improve
the management of Alzheimer’s disease,
a disease for which there is currently no
objective diagnostic. Given that anti-
bodies play not only pathogenic but also
protective roles in Alzheimer’s disease
(Britschgi et al., 2009; Vacirca et al.,
2010), searching for antibodies whose
levels are abnormally low in Alzheimer’s
disease patients may lead to the dis-
covery of additional biomarkers.
Although the authors’ approach is
compelling, key questions remain about
its clinical usefulness and its ability to
uncover antibodies that are meaningful
in terms of pathogenesis. Are the Alz-
heimer’s antibodies identified in this study
true biomarkers of Alzheimer’s disease?
Do the findings in the mouse model of
multiple sclerosis translate to the human
disease? Do the antibodies detected in
Alzheimer’s disease target primary anti-
gens,ordo they target secondaryantigens
that might be unrelated to the pathogen-
esis of the disease? Knowing the identity
of the relevant antigen in each disease is
crucial for understanding disease patho-
genesis and developing targeted thera-
pies. Although not its primary objective,
the peptoid assay could lead to the
identification of endogenous targets of
antibodies, if the antibodies captured in
the peptoid assay are used to fish the
complementary antigen out of serum.
But as Reddy et al. argue, for an anti-
body to be a useful biomarker, knowledge
of its antigen is not necessary. In fact,
antibodies of unknown specificity are
already used in clinical diagnosis. For
example, the cyclic citrullinated peptide
test (CCP), which diagnoses rheumatoid
arthritis, measures antibody binding to
a collection of synthetic citrullinated
peptides (Whiting et al., 2010). A big
difference between the CCP test and
a potential peptoid-based test, however,
is this: Whereas the CCP test is the culmi-
nation of decades of research identifying
citrullination as a key immunogenic
process in rheumatoid arthritis, a pep-
toid-based test, requiring no prior knowl-
edge of the disease at hand, could be
developed in a fraction of that time.
Thus, this new approach could prove tobe of tremendous value in clinically
managing the many immune-mediated
diseases whose pathogenesis is unclear.REFERENCES
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